|
KMID : 1007020090070020075
|
|
Korean Soceity of Osteroporosis
2009 Volume.7 No. 2 p.75 ~ p.83
|
|
|
Gateway to Clinical Prescription about Zoledronic Acid
|
|
Kim Heung-Yeol
|
|
|
Abstract
|
|
|
|
Osteoporosis is a preventable disease associated with substantial morbidity and mortality characterized by loss of bone mineral density, progression to diminished skeletal integrity, extensive bone fragility, and an increased risk of fracture. Fractures are an important cause of disability among postmenopausal women, and the public health costs are substantial. Bisphosphonates, the most commonly used treatment for established osteoporosis, inhibit osteoclast-mediated bone resorption and reduce the risk of vertebral fracture. Intravenous zoledronic acid 5 mg once yearly is effective in reducing the risk of several types of fracture in patients with postmenopausal osteoporosis or recent low-trauma hip fracture. Moreover, improvements in BMD and reductions in markers of bone turnover are also generally observed. Zoledronic acid is generally well tolerated. Additional comparative data are required to definitively position zoledronic acid with respect to other agents. In the meantime, intravenous zoledronic acid 5 mg once yearly is a convenient and effective treatment option that may have an advantage over some other agents, for which adherence to treatment regimens is a recognized problem.
|
|
|
KEYWORD
|
|
|
Osteoporosis, Zoledronic acid, Treatment
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|